Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Krystal A Orlando

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Neuroscience Journal|July 6, 2019
Sequential Changes in Brain Glutamate and Adenosine A1 Receptors May Explain Severity of Adolescent Alcohol Withdrawal after Consumption of High Levels of AlcoholPatrycja Bolewska, Bryan I Martin, Krystal A Orlando, et al.
Current Opinion in Structural Biology|July 5, 2021
The estrogen receptor/GATA3/FOXA1 transcriptional network: lessons learned from breast cancerElizabeth M Martin, Krystal A Orlando, Kosuke Yokobori, et al.
Expert Review of Anticancer Therapy|April 16, 2019
Remodeling the cancer epigenome: mutations in the SWI/SNF complex offer new therapeutic opportunitiesKrystal A Orlando, Vinh Nguyen, Jesse R Raab, et al.
The Journal of Pathology|April 27, 2017
The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic typeYemin Wang, Shary Yuting Chen, Anthony N Karnezis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2020
Small-Cell Carcinoma of the Ovary, Hypercalcemic Type-Genetics, New Treatment Targets, and Current Management GuidelinesMarc Tischkowitz, Sidong Huang, Susana Banerjee, et al.
Molecular Cancer Therapeutics|September 21, 2018
Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic TypeYemin Wang, Shary Yuting Chen, Shane Colborne, et al.
Iscience|February 5, 2025
Super-enhancers and efficacy of triptolide in small cell carcinoma of the ovary hypercalcemic typeJessica D Lang, William Selleck, Shawn Striker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2018
Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase InhibitionJessica D Lang, William P D Hendricks, Krystal A Orlando, et al.
Cancer Research|May 23, 2025
Loss of SMARCA4 Leads to Intron Retention and Generation of Tumor-Associated Antigens in Small Cell Carcinoma of the Ovary, Hypercalcemic TypeElizabeth A Raupach, Apurva M Hegde, Krystine Garcia-Mansfield, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Neuroscience Journal|July 6, 2019
Sequential Changes in Brain Glutamate and Adenosine A1 Receptors May Explain Severity of Adolescent Alcohol Withdrawal after Consumption of High Levels of AlcoholPatrycja Bolewska, Bryan I Martin, Krystal A Orlando, et al.
Current Opinion in Structural Biology|July 5, 2021
The estrogen receptor/GATA3/FOXA1 transcriptional network: lessons learned from breast cancerElizabeth M Martin, Krystal A Orlando, Kosuke Yokobori, et al.
Expert Review of Anticancer Therapy|April 16, 2019
Remodeling the cancer epigenome: mutations in the SWI/SNF complex offer new therapeutic opportunitiesKrystal A Orlando, Vinh Nguyen, Jesse R Raab, et al.
The Journal of Pathology|April 27, 2017
The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic typeYemin Wang, Shary Yuting Chen, Anthony N Karnezis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2020
Small-Cell Carcinoma of the Ovary, Hypercalcemic Type-Genetics, New Treatment Targets, and Current Management GuidelinesMarc Tischkowitz, Sidong Huang, Susana Banerjee, et al.
Molecular Cancer Therapeutics|September 21, 2018
Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic TypeYemin Wang, Shary Yuting Chen, Shane Colborne, et al.
Iscience|February 5, 2025
Super-enhancers and efficacy of triptolide in small cell carcinoma of the ovary hypercalcemic typeJessica D Lang, William Selleck, Shawn Striker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2018
Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase InhibitionJessica D Lang, William P D Hendricks, Krystal A Orlando, et al.
Cancer Research|May 23, 2025
Loss of SMARCA4 Leads to Intron Retention and Generation of Tumor-Associated Antigens in Small Cell Carcinoma of the Ovary, Hypercalcemic TypeElizabeth A Raupach, Apurva M Hegde, Krystine Garcia-Mansfield, et al.
Pageof 1